Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1365 | Elisa-test for IgM and IgG to SARS-CoV-2 Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003139 | Common Cold NIH | 0.58 |
| D008173 | Lung Diseases, Obstructive NIH | 0.27 |
| D029424 | Pulmonary Disease, Chronic Obstructive NIH | 0.26 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0006536 | Pulmonary obstruction HPO | 0.27 |
| HP:0006510 | Chronic pulmonary obstruction HPO | 0.26 |
| HP:0011947 | Respiratory tract infection HPO | 0.16 |
Navigate: Correlations HPO
There is one clinical trial.
During the COVID-19 pandemic several countries have seen a high risk of transmission for health care personnel, with some countries having as many 20-25% of nurses and doctors either infected or showing symptoms of COVID-19. In this prospective cohort study, we will systematically screen all hospital staff in the Capital Region of Denmark for IgM and IgG antibodies against SARS-CoV-2 using a point of care tests and an Elisa kit. Testing will be offered 3 times: In April 2020, Maj 2020 and September 2020. All participants will submit a questionnaire regarding exposures, risk factors and symptoms of COVID-19 in relation to each testing. Follow-up will be through electronic patient records and national registries. We will compare the group of health care personnel with data from a control group of healthy volunteer blood donors from the Danish Blood Donor Study. The aim of the study is to investigate the proportion of hospital staff with SARS-CoV-2 antibodies during the study period compared to a control group representing the Danish population. We will compare the test characteristics of the two methods of testing, a point of care test and Elisa. Further, we will investigate the extent to which prior immunization or infection is protective for future infection with COVID-19.
Description: Proportion of hospital staff who have a positive IgM/IgG tests for antibodies to SARS-CoV-2 on point of care test and/or Elisa compared to the background population
Measure: Positive IgM/IgG tests Time: At inclusionDescription: Proportion of hospital staff who have a positive IgM/IgG tests for antibodies to SARS-CoV-2 on point of care test and/or Elisa compared to the background population
Measure: Positive IgM/IgG tests Time: 1 monthDescription: Proportion of hospital staff who have a positive IgM/IgG tests for antibodies to SARS-CoV-2 on point of care test and/or Elisa compared to the background population
Measure: Positive IgM/IgG tests Time: 5 monthDescription: Comparison of the resultat from the point of care test and with results from Elisa
Measure: Comparison of the point of care test and Elisa Time: At inclusionDescription: Comparison of the resultat from the point of care test and with results from Elisa
Measure: Comparison of the point of care test and Elisa Time: 1 monthsDescription: Comparison of the resultat from the point of care test and with results from Elisa
Measure: Comparison of the point of care test and Elisa Time: 5 monthsDescription: Number of patients, who were tested positive for antibodies on an earlier test and later are infected with COVID-19
Measure: Re-infection rate Time: 180 daysDescription: Number of patients, who were tested positive for antibodies on an earlier test and later are infected with COVID-19
Measure: Re-infection rate Time: 360 daysDescription: Proportion of IgM/IgG positive participants with a lasting immune response. This will be the participants who are still positive on follow-up
Measure: IgM/IgG positive participants on follow-up test Time: 1 monthDescription: Proportion of IgM/IgG positive participants with a lasting immune response. This will be the participants who are still positive on follow-up
Measure: IgM/IgG positive participants on follow-up test Time: 5 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports